Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new study.

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

A recent study suggests that a class of diabetes medications could be linked to a reduced risk of developing dementia ...

A class of drugs used to treat diabetes has been linked to a 20% lower risk of dementia and Parkinson's disease. | ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Event offered participants essential knowledge on diabetes, focusing on key topics such as patient empowerment, innovative ...

A study indicates that SGLT2 inhibitors, a class of diabetes medications, may reduce the risk of dementia and Parkinson’s ...